コンテンツへスキップ
Merck

Management of epidermolysis bullosa acquisita.

Dermatologic clinics (2011-09-20)
Lizbeth R A Intong, Dédée F Murrell
要旨

Epidermolysis bullosa acquisita is a rare and debilitating autoimmune mucocutaneous blistering disease caused by autoantibodies directed against type VII collagen or anchoring fibrils in the subepidermal basement membrane zone. Treatment is quite challenging because this disease can be recalcitrant to multiple modalities. This article discusses the current management of this disease.

材料
製品番号
ブランド
製品内容

Supelco
スルファピリジン, ≥99.0%
Supelco
スルファピリジン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
スルファピリジン, VETRANAL®, analytical standard